Pengaruh CYP2D6 terhadap Kegagalan Terapi Primakuin pada Malaria Vivaks
Abstract
Keywords
Full Text:
PDFReferences
Hulden L, Hulden L. Activation of the hypnozoit: a part of Plasmodium vivax life cycle and survival. Malar J 2011; 10:90
Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, et al. Randomized, open label trial of primaquine against vivax malaria relapse in Indonesia. AAC 2013;57:1128-35
Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J 2011;10:351
Galappaththy GNL, Tharyan P, Kirubakaran R. Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine (Review). The Cochrane Library 2013;10
Naing C, Whittaker MA, Wai VN, Mak JW. Is Plasmodium vivax malaria a severe malaria?: A systematic review and meta-analysis. Plos Negl Trop Dis 2014;8(8):e3071
Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg. 2007;77(6):79-87
Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 2001;64:97-106
Vinetz JM, Clain J, Bounkeua V, Eastman RT, Fidock D. Chemotherapy of malaria. In: Brunton L, Chabner B, Knollman B, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th ed. New York: Mc Graw Hill; 2011. p.1383-418. 9. Ingram RJH, Darusallam CC, Soebianto S, Noviyanti R, Baird JK. The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. Malar J 2014;13:488
Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J 2014;13:418
Baird JK. Effectiveness of Antimalarial Drugs. N Engl J Med 2005;352:1565-77
Davanco MG, Aguiar ACC, Santos LA, Padilha EC, Campos ML, Andrade CR, et al. Evaluation of antimalarial activity and toxicity of new primaquine prodrug. Plos one 2014;9(8):e105217
Fasinu PS, Tekwani BL, Nanayakkara D, Avula B, Herath HMTB, Wang YH, et al. Enatioselective metabolisme of primaquine by human CYP2D6. Malar J 2014; 13:507
Myint HY, Berman J, Walker L, Pybus B, Melendez V, Baird JK, et al. Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combination: Review of the literature and proposal for future investigations. Am. J. Trop. Med. Hyg 2011;85(6):1010-14
Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J 2013;12:212. 16. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magil AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006;75:402-15
Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab 2011;12(5):487-497
Bennet JW, Pybus BS. Yadava A, Tosh D, Causa JC. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013; 369:14
DOI: https://doi.org/10.32502/sm.v5i1.1419
Refbacks
- There are currently no refbacks.
Copyright (c) 2019 Kamalia Layal, Anggi Gayatri
![Creative Commons License](http://licensebuttons.net/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.